On March 10, 2025, Humacyte, Inc. announced the publication of the Budget Impact Model (BIM) for Symvess in the Journal of Medical Economics. The publication, titled 'Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible,' projected Symvess to be cost-saving for trauma centers and third-party payers.
The model indicated average per-patient costs for trauma centers at $121,615 for Symvess, compared to figures ranging from $137,213 to $154,722 for synthetic and other non-autologous grafts. For commercial payers, estimated per-patient costs were significantly lower for Symvess ($94,165) compared to approximately $180,000 for other grafts.
The primary drivers of these cost savings were attributed to reductions in vascular conduit infections and amputations. This economic validation is a key component of Humacyte's commercial strategy, supporting Value Analysis Committee approvals and market penetration for Symvess.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.